Story thread · 2 reports / 2 sources

ECRI, ISMP warn against FDA panel’s peptide compounding vote

beckershospitalreview.com · 14dShare

Patient safety groups are warning that an FDA advisory committee’s decision to recommend expanding compounding access to wellness peptides came without the safety and efficacy evidence needed to justify it. The FDA’s Pharmacy Compounding Advisory Committee voted during its July 23-24 meeting to recommend adding six of the seven peptides under review to the 503A […] The post ECRI, ISMP warn against FDA panel’s peptide compounding vote appeared first on Becker's Hospital Review | Healthcare News & Analysis .

First report: Evidence vs influencers: The FDA vote putting patients in danger — washingtonexaminer.com, 15d